Navigation Links
Engineer to spearhead research into cell metabolism and medical injuries
Date:5/9/2008

A University of Leicester engineer has won a share of grants totalling over 1m to target lung injury and cancer.

In an unusual move, Dr. Declan Bates, a senior lecturer in the Department of Engineering at the University of Leicester, is co-recipient of 1,068,000 in the form of just two research grants: one from the Engineering and Physical Sciences Research Council (EPSRC) and the other from the Biotechnology and Biological Sciences Research Council (BBSRC).

The grants are shared between academics at Leicester and Nottingham and Aberdeen.

The first will be used to examine how lung injury can be prevented in patients who are on ventilators; the second, to investigate a potential target for future cancer treatments.

These may seem worlds apart -especially for an engineer, but theyre united by a common factor feedback control theory which of course is a science in its own right, said Dr Bates.

He added: It might seem odd that a life-support machine can cause injury, but this is actually not uncommon. The majority of critically ill patients in Intensive Therapy Units (ITU) spend some time with their lungs ventilated using a mechanical ventilator or life-support machine. However, mechanical ventilation exposes patients lungs to potentially damaging positive pressures, and as a result, ventilator-associated lung injury (VALI) is a common and significant occurrence. Prolonged stays in the ITU may be generated, pneumonia may be precipitated and lifelong lung scarring may result. The scale of the problem is such that 2.9% of people receiving mechanical ventilation suffer VALI each year, which represents several thousand individuals in the UK each year.

Dr Bates will be looking at these problems in terms of feedback control in order to find ways to optimally adjust the ventilators to allow them to do their job better while minimising injury. This is highly complicated, and previous attempts have had to rely on idealised subjects. Dr Bates will perform population modelling, making his findings applicable to real patients.

With the second grant, Dr Bates will investigate how biochemical pathways are regulated in human cells, which could lead to improved anti-cancer drugs.

A class of molecules called polyamines are crucial to the health of the cells in your body. Cells normally regulate polyamine levels very tightly as changes in their concentrations can cause the cells to die, become cancerous, or give rise to other diseases.

Understanding how various biological control processes interact to keep everything on an even keel is a tall order, and one that can only be addressed with the new field of Systems Biology.

Dr Bates will draw on the expertise of biologists and control engineers to mathematically model the pathways involved. This will teach us how the control systems operate and how cells stay healthy, but should ultimately lead to therapies specific to the problems that arise when they go wrong.

Dr. Bates says:

This interdisciplinary approach is required as a direct response to the complexity of the mechanisms being studied, which renders standard biological approaches inadequate.


'/>"/>

Contact: Dr. Declan Bates
dgb3@le.ac.uk
University of Leicester
Source:Eurekalert

Related biology news :

1. Prof. David Kisailus studies engineering and invention on the half-shell
2. McMaster University engineering professor receives Humboldt Research Award
3. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
4. Genetic Engineering & Biotechnology News reports on cancer biomarkers
5. Brown hosts regional bioengineering conference
6. Scientists find that squid beak is both hard and soft, a material that engineers want to copy
7. Small desert beetle found to engineer ecosystems
8. Chemical engineers discover new way to control particle motion
9. Springer expands publishing partnership with the Biomedical Engineering Society
10. Policing cells demand ID to tell friend from foe, say University of Pennsylvania cell engineers
11. Metabolic Engineering VII
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: